Evidence map›Paper›PMID 25123250›Full record

ArticleArthritis research & therapy2014

Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts.

Pei-Suen Tsou, Beatrix Balogh, Adam J Pinney, George Zakhem, Ann Lozier, M Asif Amin, William A Stinson, Elena Schiopu, Dinesh Khanna, David A Fox and 1 more

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Lipid Alterations in Systemic Sclerosis.Frontiers in molecular biosciences · 2021
    Review
  6. Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  7. NEDD9 targetsScience translational medicine · 2018
    Article
  8. Article
  9. Article
  10. Pathogenesis of Systemic Sclerosis.Frontiers in immunology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Pei-Suen TsouDepartment of Internal Medicine, Division of Rheumatology, University of Michigan Medical School, 109 Zina Pitcher Dr., 4388 BSRB, Ann Arbor, MI 48109-2200, USA. ptsou@umich.edu
Beatrix Balogh
Adam J Pinney
George Zakhem
Ann Lozier
M Asif Amin
William A Stinson
Elena Schiopu
Dinesh Khanna
David A Fox
Alisa E Koch
University of Michigan–Ann Arbor · USScleroderma Foundation · US

Funding

TRAINING OF ARTHRITIS RESEARCH SCIENTISTST32AR007080 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jason Knight · 1986 to 2026
$6.3M
Outcomes Research in Rheumatic DiseasesK24AR063120 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2012 to 2022
$1.6M
NCI NIH HHS CA46952NIAMS NIH HHS K24 AR063120NIAMS NIH HHS K24 AR063120-02NIAMS NIH HHS T32 AR007080
6 · The paper itself

Abstract

introductionSystemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis of the skin and organs. Increase in oxidative stress and platelet-derived growth factor receptor (PDGFR) activation promote collagen I (Col I) production, leading to fibrosis in SSc. Lipoic acid (LA) and its active metabolite dihydrolipoic acid (DHLA) are naturally occurring thiols that act as cofactors and antioxidants, and are produced by lipoic acid synthetase (LIAS). The goal of this study was to examine whether LA and LIAS was deficient in SSc patients and determine the effect of DHLA on the phenotype of SSc dermal fibroblasts. N-acetylcysteine (NAC), a commonly used thiol antioxidant, was included as a comparison.

methodsDermal fibroblasts were isolated from healthy subjects and patients with diffuse cutaneous SSc. Matrix metalloproteinase (MMPs), tissue inhibitors of MMPs (TIMP), plasminogen activator inhibitor-1 (PAI-1) and LIAS were measured by ELISA. The expression of Col I was measured by immunofluorescence, hydroxyproline assay, and quantitative PCR. PDGFR phosphorylation and α-smooth muscle actin (α-SMA) was measured by Western blotting. Student's t-tests were performed for statistical analysis and p-values of less than 0.05 with two-tailed analysis were considered statistically significant.

resultsThe expression of LA and LIAS in SSc dermal fibroblasts was lower than normal fibroblasts, however LIAS was significantly higher in SSc plasma and appeared to be released from monocytes. DHLA lowered cellular oxidative stress, and decreased PDGFR phosphorylation, Col I, PAI-1, and α-SMA expression in SSc dermal fibroblasts. It also restored the activities of phosphatases that inactivated the PDGFR. SSc fibroblasts produced lower levels of MMP-1 and 3, and DHLA increased them. In contrast, TIMP-1 levels were higher in SSc but DHLA had minimal effect. Both DHLA and NAC increased MMP-1 activity when SSc cells were stimulated with PDGF. In general, DHLA showed better efficacy than NAC in most cases.

conclusionsDHLA not only acts as an antioxidant but also an antifibrotic since it has the ability to reverse the profibrotic phenotype of SSc dermal fibroblasts. Our study suggests that thiol antioxidants, including NAC and LA/DHLA, could be beneficial for patients with SSc.

Indexed as

AdultBlotting, WesternCells, CulturedCollagen Type IDermisFemaleFibroblastsGene ExpressionHumansMaleMatrix MetalloproteinasesMiddle AgedOxidative StressPhosphorylationPlasminogen Activator Inhibitor 1Protein Tyrosine Phosphatase, Non-Receptor Type 11Collagen Type Idihydrolipoic acidlipoic acid synthaseMatrix MetalloproteinasesPlasminogen Activator Inhibitor 1Protein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanPTPRJ protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 3Receptors, Platelet-Derived Growth FactorSulfurtransferasesThioctic AcidTissue Inhibitor of Metalloproteinases

Identifiers

PMID25123250
PMCPMC4558991
OpenAlexW2094283286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.